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Background: History of gestational diabetes mellitus (GDM) identifies a very young population of females
predisposed for type 2 diabetes and cardiovascular disease. Endothelial dysfunction might represent a shared
precursor of both disorders. Hence, this study aimed to characterize endothelial biomarkers in relation to impaired
insulin sensitivity and progression to overt diabetes early after index pregnancy.
Methods: 108 women with previous GDM and 40 controls were included three to six months after delivery and
underwent specific metabolic assessments including a frequently sampled intravenous glucose tolerance test and
an oral glucose tolerance test. Diabetes progression was assessed in females with pGDM over 10 years of follow-up.
Circulating sICAM-1 (intracellular-adhesion-molecule-1), sVCAM-1 (vascular-cell-adhesion-molecule-1) and sE-selectin,
representing biomarkers of endothelial dysfunction were assessed at baseline and annually over five years.
Results: Endothelial biomarkers were significantly associated with insulin sensitivity (sICAM-1: r = -0.23, p = 0.009;
sVCAM-1: r = -0.22, p = 0.011; sE-selectin: r = -0.21, p = 0.018) as well as with GDM status and parameters of subtle
inflammation. Analysis of long-term trajectories revealed constantly elevated sICAM-1 (p = 0.033) and sE-selectin
(p = 0.007) in 25 subjects with diabetes progression. Accordingly, sE-selectin levels at the early post partum visit
predicted a later development of the disease (HR =1.02 95%CI 1.01 to 1.04, p = 0.013), however, this was attenuated
after adjustment for BMI.
Conclusions: Elevated circulating markers of endothelial dysfunction in young females with GDM history might
reflect an early stage on the pathway to the manifestation of future cardiometabolic disorders. Timely identification
of women at high risk and optimization of follow-up management might provide an opportunity to prevent disease
progression.
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Endothelial dysfunction characterizes a state of dysba-
lance between vasoconstriction and vasodilatation pre-
disposing atherosclerosis and cardiovascular disorders
(CVD), the principal complications of type 2 diabetes
[1,2]. This process starts already several years before the
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unless otherwise stated.hyperglycemia is accompanied by inflammation and endo-
thelial damage [1-4]. In addition it was supposed, that
dysfunctional endothelium by itself aggravates impaired
glucose disposal, mainly due to the loss of vasoactive
properties mediated by insulin (i.e. total blood flow as well
as the regulation of capillary perfusion in insulin sensitive
tissues) [3,5,6]. At the same time the expression of cellular
adhesion molecules (CAMs) and selectins on the surface
of the endothelium is up-regulated, inducing tethering
and firm adhesion of leucocytes, maintaining inflamma-
tion and hence further promoting an atherogenic milieu
[6,7]. Consequently, endothelial dysfunction was suggestedd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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hyperglycemic disorders [8]. However, clinical conse-
quences in different risk populations are not thoroughly
investigated until now [5].
Females with history of gestational diabetes mellitus
(GDM) are of particular interest for studying the rela-
tionship between endothelial dysfunction, impaired insu-
lin sensitivity and cardiometabolic disorders, as this high
risk entity represents the earliest stage of a prediabetic
condition suffering from an increased risk for develop-
ing type 2 diabetes [9] but also CVD [10,11]. In this
context, previous observational studies indicated that
obesity and impaired glucose metabolism during the
pregnant state is associated with markers of endothelial
dysfunction [12], which might also be apparent in the
postpartal period [13,14]. However, data on this issue is
contradictory [15].
Therefore, this report aims to assess three main objec-
tives: (i) to describe the association of soluble cellular
adhesion molecules including, sICAM-1 (soluble intracel-
lular adhesion molecule-1), sVCAM-1 (soluble vascular
cell adhesion molecule-1) as well as soluble E-selectin
(sE-selectin) with impaired insulin sensitivity early after
pregnancy with GDM; (ii) to examine long-term trajector-
ies of these parameters as well as (iii) their association
with the later development of type 2 diabetes. As a sec-
ondary objective, the impact of impaired insulin sensitivity
and history of GDM with increased carotid intima media
thickness (IMT) a well established marker of early athero-
sclerosis should be examined in a subgroup.
Methods
Study participants
The study design of the “Vienna Post-Gestational Diabetes
Project” was reported elsewhere e.g. [16-18]. For the
present report we included data of 108 females 3–6
months after pregnancy with GDM (pGDM) and 40 con-
trols (women after gestation without GDM) with available
data of soluble adhesion molecules or IMT (2 pGDMs
and 1 control subject were excluded from the original
study cohort due to missing data of these parameters).
Diagnoses of GDM was performed according to [19]
by a 75 g-OGTT between June 1999 and December
2003.
Experimental procedures and calculations
Participants received a metabolic characterization at the
baseline examination including soluble biomarkers of
endothelial dysfunction (i.e. sICAM-1, sVCAM-1, sE-
selectin) as well as a 75 g-OGTT after at least 8 hours
fasting with measurements of glucose, insulin and C-
peptide. A 3 h frequently sampled intravenous glucose
tolerance test (FSIGT) was additionally performed at the
baseline visit (details of this examination are reportedelsewhere e.g. [17,20]) to assess the insulin sensitivity
index (SIFSIGT) by minimal model analysis according to
[21,22]. For group based comparisons pGDMs were di-
vided into insulin sensitive (pGDM-IS) or insulin resist-
ant subjects (pGDM-IR) by using the previously defined
cut-off of SI = 2.8 × 10−4 min−1/(μU/ml) [23]. Insulin se-
cretion from FSIGT (ΔAIRG) was estimated by the in-
cremental short-term insulin response (3–10 min) after
intravenous glucose load [24]. Insulin sensitivity was
additionally estimated from OGTT data by using the
oral glucose insulin sensitivity index (OGIS) [25] and in-
sulin secretion from OGTT data was assessed by the
insulinogenic index (IGI = Δinsulin30/Δglucose30) [26].
Biomarkers of endothelial dysfuction were reexamined
within 12 to 18 month after the baseline visit in females
with pGDM over a period of approximately five years
(median: 59 month, IQR: 50 - 62 month). OGTTs were
annually repeated in the pGDM subgroup over up to 10
years of follow-up (until March 2013) to identify subjects
with diabetes manifestation (median: 81.5 month, IQR:
51 – 142 month for subjects included in the present re-
port). Overt diabetes was diagnosed, if FPG or 2 h post
load glucose levels exceeded 126 mg/dl or 200 mg/dl.
IMT measurements were performed by a ATL (Ad-
vanced Technology Laboratories, Bothell, Washington
98021 USA), HDI 5000 system. A linear array, 12–5
MHz Probe was employed. To keep variabilities to a
minimum the primary measurements were performed in
the distal common carotid artery, 1 cm proximal to the
carotid bulb on the far vessel wall in two angles of the
transducer; secondary measurements were performed
proximally and distally to this point in the common and
in the proximal internal carotid artery with assessment
of the far vessel wall by an experienced coinvestigator
blinded to any additional clinical information. The aver-
age of these measurements was used for further analyses.
Carotid IMT were performed in n =69 subjects (n =54
pGDMs and n =15 controls) 60 month (IQR: 19.5 – 65
month) after the baseline examination. 14 subjects had a
repeated measurement during this period.
The study was approved by the Ethics Committee of
the Medical University of Vienna and performed in ac-
cordance with the Declaration of Helsinki. All partici-
pants gave written informed consent.
Laboratory methods
Plasma glucose (Beckman, Fullerton, CA); Insulin (radio-
immunoassay, Serono Diagnostics); C-Peptide (radio-
immunoassay, CIS Bio International); Adhesion molecules
(ELISA, British Biotechnology Product Ltd.); PAI-1 (ELISA,
Technoclone); IL-6 (ELISA, R&D Systems); usCRP (N
High Sensitivity CRP Reagent, BN Systems); sICAM-1,
sVCAM-1, sE-selectin (ELISA, British Biotechnology Prod-
uct Ltd.).
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Baseline data were summarized by means and standard
deviations (SD) in case of continuous variables as well as
by counts and percentages in case of categorical vari-
ables. Differences of metric scaled parameters in more
than two groups were assessed by analysis of variance
(ANOVA). Linear trend analysis was used to assess
trends of endothelial biomarkers according to subgroups
categorized by their status of insulin sensitivity. The in-
fluence of continuous covariates on sICAM-1, sVCAM-1
and sE-selectin was assessed by correlation analysis
(Pearson’s product moment correlation or Spearman’s
rank correlation) and multivariable regression models,
respectively. Fractional polynomials (by using a back-
ward selection algorithm for suitable transformations as
proposed by [27] with a family-wise error rate of 5%)
were used to model the relationship between endothelial
biomarkers and insulin sensitivity. Data transformations
were performed in case of skewed distributed baseline
variables: PAI-1, triglycerides: ln(x); usCRP, IL-6: ln(x +1).
The proportional hazard model (and a survival regression
for sensitivity analyis to account for interval censoring)
was used to examine the associations of sICAM-1,
sVCAM-1 and sE-selectin with the incidence of type 2
diabetes during the follow-up period. Analyses of longitu-
dinal data were examined by linear mixed effects models
(random intercepts and random slopes by subjects). For
some models the random slope was excluded if this was
necessary to achieve convergence. A spatial exponential
covariance structure was used to model the correlations
between repeated measurements. sICAM-1 and sVCAM-
1 were log transformed (ln(x)) and sE-selectin was square
root transformed (sqrt(x)) for longitudinal analyses. IMT
data (83 measurements in 69 subjects) was analysed by
using a random intercept model accounting for corre-
lated residuals due to repeated measurements in some
subjects. In case of linear relationships regression coeffi-
cients (β) represent the mean change in the dependent
variable for the increase of the independent variable byTable 1 Baseline characteristics categorized by insulin sensiti
n Controls n
Age (years) 40 31.2 ± 5.7 63
BMI (kg/m2) 37 25.2 ± 5.6 63
OGIS, ml min−1 m−2 39 490.1 ± 71.0 63
SI, 10−4 min−1 (μU/ml)−1 38 5.4 ± 2.6 63
ΔAIRg (μu/ml) 38 54.4 ± 42.8 63
sICAM-1 (ng/ml) 39 238.0 ± 54.1 61
sVCAM-1 (ng/ml) 39 502.3 ± 164 61
sE-selectin (ng/ml) 34 45.1 ± 18.5 61
Data are means ± standard deviation. BMI (body mass index), OGIS (oral glucose insulin
sICAM-1 (soluble intracellular adhesion molecule-1), sVCAM-1 (soluble vascular cell adh
*p-values are based on a test of linear trend.one unit. If the independent variable is a factor (e.g.
GDM status) they can be interpreted as the mean differ-
ences of factor levels (i.e. GDM vs. NGT), adjusted for
other variables in the model.
Statistical analysis was performed with R (V3.0.2) and
contributed packages (particularly the R-packages “mfp”,
“nlme”, “survival” for data analysis as well as “lattice”
and “beeswarm” for visualizations) [28]. The two sided
significance level was set to 0.05. No adjustment for
multiplicity was considered for this observational study.Results
Associations of endothelial biomarkers with insulin
sensitivity, GDM status and subclinical inflammation at
the early postpartum period
A brief summary of the study sample in Table 1 shows
that biomarkers of endothelial dysfunction at the base-
line examination were highest in the pGDM-IR sub-
group (Figure 1). This observation was also confirmed
by analyses of continuous data, as sICAM-1, sVCAM-1,
and sE-selectin were inversely related to SIFSIGT 3–6
month after delivery (Table 2). Regression models based
on fractional polynomials revealed monotonic but non-
linear relationships between insulin sensitivity at baseline
(SIFSIGT) and sICAM-1 as well as sE-selectin, which
were used in multivariable models (Figure 2). However,
no association were observed between endothelial bio-
markers and insulin secretion (Table 2).
Multivariable analyses including status of GDM during
pregnancy in addition to age, BMI and SIFSIGT showed
that females with history of GDM had significantly ele-
vated levels of adhesion molecules as compared to control
subjects: sICAM-1: β =55.2, 95%CI 27.5 to 82.9, p <0.001;
sVCAM-1: β =109.2, 95%CI 31.6 to 186.9, p =0.006. How-
ever, no differences were observed for sE-selectin (β =4.30,
95%CI −5.25 to 13.85, p =0.374 for pGDM vs. controls),
which was best explained by BMI levels (β =1.39, 95%CI
0.43 to 2.35, p =0.005). The models explained 21.2%vity status
pGDM-IS n pGDM-IR p-value
32.8 ± 4.2 39 32.9 ± 5.7 0.203
25.0 ± 3.5 39 30.5 ± 5.6 <0.001
463.6 ± 68.6 39 395.3 ± 72.7 <0.001
5.3 ± 2.3 39 1.7 ± 0.6 <0.001
36.0 ± 22.7 39 50.3 ± 38.6 0.017
295.3 ± 70.5 35 304.1 ± 92.2 <0.001*
600.3 ± 220 35 647.7 ± 159 0.001*
48.6 ± 22.4 36 57.4 ± 27.4 0.026*
sensitivityindex), SI (insulin sensitivity index), ΔAIRg (acute insulin response),




























































Figure 1 Bee swarm plot of endothelial biomarkers at baseline in different subgroups: normal glucose tolerant controls (NGT) as well
as females after pregnancy with GDM grouped by insulin resistance status (pGDM-IS: insulin sensitive; pGDM-IR: insulin resistant):
A: sICAM-1; B: sVCAM-1; C: sE-selectin. Lines indicate first, second (median) and third quartiles.
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the variances, respectively.
Correlation analyses showed significant associations
between serum lipid levels as well as parameters of
subclinical inflammation and endothelial biomarkers
(mainly sICAM-1 and sE-selectin, Table 2). sICAM-1
remained significantly associated with HDL-cholesterol
and usCRP also after adjustment for age, BMI, SIFSIGT
and status of GDM (GDM vs. controls): HDL-cholesterol:
β = −0.97, 95%CI −1.86 to −0.09, p = 0.032; usCRP:
β = 62.9, 95%CI 9.80 to 116.1, p = 0.021 (for log transformedTable 2 Correlation of endothelial biomarkers and characteris
sICAM-1
n r p-value n
age 140 0.05 n.s. 140
BMI 136 0.25 0.004 136
RRS 131 0.14 n.s. 131
RRD 131 0.11 n.s. 131
SI (FSIGT)* 133 −0.23 0.009 133
OGIS (OGTT)* 137 −0.18 0.033 137
ΔAIRg (FSIGT)* 133 −0.09 n.s. 133
IGI (OGTT)* 139 −0.12 n.s. 139
Total-Cholesterol 140 −0.03 n.s. 140
LDL-Cholesterol 137 0.08 n.s. 137
HDL-Cholesterol 140 −0.30 0.001 140
ln(Triglycerides) 140 0.12 n.s. 140
ln(usCRP) 116 0.28 0.003 116
ln(IL-6) 93 0.13 n.s. 93
ln(PAI-1) 132 0.29 <0.001 132
Fibrinogen 140 0.25 0.003 140
Data are number of observarion (n) and correlation coefficients (r). BMI (body mass
sensitivity index derived from the FSIGT), OGIS (oral glucose tolerance index derived
FSIGT), IGI (insulinogenic index), HDL (high density lipiprotein), LDL (low density lipo
(plasminogen activator inhibitor 1).
*Spearman’s rank correlation as used instead of Pearson’s product moment correlatdata), whereas associations of inflammatory parameters
and sE-selectin were attenuated.
We found no evidence of strong effect modification (i.e.
interaction) of continuous associations by GDM status.
Association of endothelial biomarkers with the later
development of overt diabetes
Trajectories of endothelial biomarkers are visualized in
Figure 3 and showed no major time related changes dur-
ing the follow-up examinations of females following
pregnancies with GDM. However, longitudinal analysistics of the study population
sVCAM-1 sE-selectin
r p-value n r p-value
0.04 n.s. 136 0.09 n.s.
0.21 0.016 132 0.35 <0.001
0.10 n.s. 128 0.12 n.s.
0.18 0.036 128 0.13 n.s.
−0.22 0.011 129 −0.21 0.018
−0.23 0.007 133 −0.12 n.s.
0.04 n.s. 129 −0.04 n.s.
0.03 n.s. 135 −0.10 n.s.
0.10 n.s. 136 −0.02 n.s.
0.13 n.s. 133 0.02 n.s.
0.06 n.s. 136 −0.16 n.s.
−0.02 n.s. 136 0.12 n.s.
0.18 n.s. 114 0.04 n.s.
0.16 n.s. 94 0.24 0.019
0.08 n.s. 128 0.21 0.016
0.04 n.s. 136 0.25 0.003
index), RRS (systolic blood pressure), RRD (diastolic blood pressure), SI (insulin
from the OGTT), ΔAIRG (acute insulin response to glucose derived from the
protein), usCRP (ultrasensitive C-reactive protein), IL-6 (interleukin-6), PAI-1
ion due to nonlinear monotonic associations or outliers.










































































Figure 2 Association of baseline sICAM-1 (A), sVCAM-1 (B) and sE-selectin (C) with SI levels and the regression curve derived from
regression analysis based on fractional polynomials.
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CI 0.009 to 0.207, p = 0.033 (for ln transformed data))
and moreover elevated sE-selectin levels (β =0.96, 95%CI
0.27 to 1.64, p = 0.007 (for sqrt transformed data)) in
n =25 female subjects with progression to overt diabetes.
The results remained constant, if subjects with a follow-
up period of less than four years (and no diabetes progres-
sion) were excluded. No interactions between trajectories
of endothelial biomarkers and progression status were
observed. In accordance, sE-selectin levels at the early
postpatum visit was significantly related to diabetes pro-
gression (HR =1.02 95%CI 1.01 to 1.04, p = 0.013 (per ng/
ml)) in the pGDM subgroup. This association remained
constant after adjustment for age (p = 0.024) but attenu-
ated after additionally adjusting for BMI (p = 0.273). Re-
garding adhesion molecules baseline sVCAM-1 levels
appeared to be not related with incident type 2 diabetes
(0.474), whereas a tendency was observed for sICAM-1
(HR = 1.01 95%CI 1.00 to 1.01, p = 0.050 (per ng/ml)).
We performed an additional sensitivity analysis treating
diabetes progression as interval censored time to event
data, however, the basic conclusions remained constant.Figure 3 Trajectories of soluble endothelial biomarkers in subjects af
(blue) or no progression (red) over the study period: sICAM-1 (A), sVCAssociation of intima media thickness with history of
GDM (subgroup analysis)
Baseline parameters associated with IMT (average) were
age (β = 0.005, 95%CI 0.002 to 0.008, p = 0.003) and more-
over status of GDM during pregnancy (β = 0.046, 95%CI
0.010 to 0.082, p = 0.013, Figure 4), whereas no association
was observed between IMT and endothelial biomarkers
(sICAM-1: p = 0.098, sVCAM-1: p = 0.581, sE-selectin:
p = 0.800) or SIFSIGT (p = 0.176) in univariable analyses. A
trend was observed for BMI (β = 0.003, 95%CI 0.00 to
0.006, p = 0.054). A multivariable model revealed that the
effects of age and GDM status remained significant after
additional adjustment for time after index pregnancy.
Discussion
In the present study we aimed to assess the relationship
between impaired insulin sensitivity and soluble parame-
ters of endothelial dysfunction in females with history of
GDM and observed inverse associations between insulin
sensitivity estimated from an FSIGT and sICAM-1,
sVCAM-1 as well as sE-selectin 3–6 month after deliv-
ery. In particular, sICAM-1 and sVCAM-1 were shownter pregnancy with GDM categorized for diabetes progression




































































Figure 4 Bee swarm plot of IMT data in a subgroup of pGDM and controls: right side (A), left side (B), average (C). Lines indicate first,
second (median) and third quartiles.
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males after uncomplicated pregnancy (controls) inde-
pendent of age, BMI and degree of insulin resistance. As
an additional finding our data indicates that circulating
biomarkers of endothelial dysfunction were related to
parameters of subtle inflammation and tended to be in-
creased in females with diabetes progression during a
follow-up period of up to 10 years.
The link between circulating biomarkers of endothelial
dysfunction and impaired carbohydrate metabolism or
type 2 diabetes has been assessed by previous observa-
tional studies: With particular focus on older females
(average of 56 years) data from the Nurses’ Health Study
indicated that endothelial biomarkers predicted the de-
velopment of overt diabetes [29]. This observation was
also confirmed by another multiethnic cohort of U.S.
postmenopausal women [30]. As endothelial biomarkers
(e.g. sICAM-1 and sE-selectin) were also related to car-
diovascular prognosis in initially health individuals [7] it
was hypothesized that dysfunctional endothelium repre-
sents a shared precursor of atherosclerosis and CVD (if
large arteries are affected) as well as insulin resistance
and type 2 diabetes (if endothelial dysfunction addresses
capillaries of insulin sensitive tissues) [8,29]. These con-
siderations are also supported by our data as we found
an inverse association between insulin sensitivity as well
as subtle inflammation and indicators of endothelial dys-
function in our study of relatively young females at a
very early stage of cardiometabolic disorders. Our find-
ings are in line with molecular and pathophysiological
consequences of insulin resistance in endothelial cells
[1,2,6]: While in metabolically healthy individuals insulin
acts as a vasoactive hormone, primarily by activating
phosphatidylinositol 3-kinase (PI3K) and consequently
nitric oxide production (due to Akt mediated phosphor-
ylation of endothelial nitiric oxide synthase), this signal-
ing pathway is notably blunted by insulin resistanceleading to impaired endothelium dependent vasodilatation.
However, due to compensatory increased insulin release
from the β-cells (hyperbolic association between insulin
sensitivity and insulin secretion [31]), insulin signaling via
the mitogen-activated protein kinase (MAPK) is stimu-
lated, mediating expression of proinflammatory parame-
ters. Hence, the expression of ICAM-1, VCAM-1 or
E-selectin on the endothelial surface is over activated with
consequently increased soluble levels in insulin resistant
individuals, also observed in our study in reproductive
aged females early after delivery. In addition, hypergly-
cemia might affect the Gas6 (growth arrest-specific protein
6)/Axl/Akt signaling pathway in human microvascular
endothel cells, as in observational and in vitro studies
Gas6 and Gas6/Axl expression was found to be downregu-
lated by increased glucose concentrations [32,33]. This
might further impact viability of endothelial cells, angio-
genesis and adhesion function and hence might represent
a possible target for future therapeutic strategies [33].
In accordance with these pathophysiological consider-
ations particularly sICAM-1 was well explained by gly-
cemic parameters and moreover significantly related to
subclinical inflammation and thrombosis in uni- and
multivariable analyses (21.2% of the variance of sICAM-1
was explained by the covariables). In contrast, sVCAM-1
was less explained in multivariable analysis (8% of vari-
ance) and failed to show any association with incident type
2 diabetes. This is in line with previous observations in
mixed populations, as sICAM-1 was shown to predict
symptomatic disorders in apparently healthy individuals
(as supposed for reproductive aged females), whereas
sVCAM-1 is more useful as a risk marker in subjects with
established disease [7]. Accordingly, another recent study
found significantly increased secretion of ICAM-1 and
other markers of endothelial cell dysfunction in human
omental tissue of women with obesity or GDM, where-
as this was not observed for VCAM-1 expression or
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(which are also expressed by other tissues) sE-selectin rep-
resents a more endothelial specific parameter, which ap-
peared to be related to subtle inflammation as well as to
type 2 diabetes development. However, it has to be men-
tioned, that in our study the predictive performance for
diabetes progression for sE-selectin (which was indicated
by univariable analysis) was blunted after adjustment for
age and particularly BMI. Therefore, we agree with Chao
et al., that from an epidemiological point of view parame-
ters of endothelial dysfunction might contribute only little
for diabetes prediction as compared to traditional risk fac-
tors including fasting glucose, body composition and clin-
ical risk factors (as was shown by the authors in a large
sample of postmenopausal women) [35]. This was also
reflected by another recent report, where sE-selectin levels
correlated with components of the metabolic syndrome,
but however, were not independently related to abnormal
glucose regulation early after delivery [36]. We have previ-
ously examined several risk factors for diabetes progres-
sion by using data of the present study and have identified
parameters of disturbed carbohydrate metabolism (e.g. 1
h-post load glucose levels which were also shown to be
significantly related to adhesion molecules) [17] but also
an index indicating non alcoholic fatty liver disease [20]
which might perform superior for risk prediction as com-
pared to the endothelial biomarkers investigated in this
study. However, we suggest that the systematic analyses of
circulating markers of endothelial dysfunction in longitu-
dinal studies are necessary for thoroughly understanding
the development of diabetic and cardiovascular disorders
as well as the interrelation between both diseases in
women following pregnancy with GDM. Moreover, ele-
vated markers of endothelial dysfunction and oxidative
stress might be also elevated in the cord blood of females
with GDM [37]. Thus, there is also need for further re-
search concerning the consequences of maternal hypergly-
cemia particularly in the view of an early onset of
endothelial dysfunction and atherosclerosis in the off-
spring due to the concept of “fetal programming”.
With regard to CVD there is emerging evidence for a
markedly increased risk for subjects with history of GDM
[38,39], however, data with clearly defined cardio-vascular
endpoints in this young aged population are sparsely avail-
able. In this study we assessed subclinical atherosclerosis as
a secondary objective and in accordance with others
[40,41] observed significantly higher IMT values in pGDMs
as compared to females after uncomplicated pregnancy,
further supporting that history of GDM should be consid-
ered as an independent vascular risk factor [41], compar-
able to the “metabolic syndrome” [40]. IMT measurements
were found to be further associated with age, but not with
adhesion molecules, measured at the baseline examination.
This is somewhat unexpected and might be observed bychance due to the limited number of IMT measures for
this secondary objective. However, previous studies re-
ported conflicting results: While one observational study
reported significant associations between IMT levels and
sICAM-1 as well as sE-selectin 6.5 years following an index
pregnancy with GDM [41], this association was not re-
vealed for older females in another study [42]. Although,
the results of the letter study indicated a markedly associ-
ation between sICAM-1 and CVD death in women [42].
Strengths and potential limitations of this report
should be addressed: The longitudinal study design as
well as repeated measurements of endothelial bio-
markers (over a period of five years of observation), as
well as the prospective reassessment of glucose tolerance
status by OGTTs (for up to 10 years) and the availability
of FSIGT data for estimating insulin sensitivity and β-
cell function at the baseline visit are the major strength
of our study. It might be criticized, that endothelial dys-
function was indirectly assessed by using measurements
of circulating biomarkers. Flow-mediated vasodilatation
might represent another popular (but also indirect)
measurement of endothelial dysfunction. However, we
decided to use the more simple approach, due to the
large number of repeated measures. In addition, it has to
be mentioned, that the evidence of some of our results
might be restricted according to the sparse number of
subjects with progression to overt diabetes, and hence
should be interpreted in a descriptive manner.
Conclusions
In summary, we found that biomarkers of endothelial dys-
function are related to impaired insulin sensitivity and
moreover notably increased in females with recent history
of GDM. Thereby sICAM-1 and sE-selectin tended to be
elevated in subjects who showed a progression to type 2
diabetes after delivery and hence possibly indicate the later
development of overt cardiometabolic disorders in this
relatively young aged risk population. Follow-up examina-
tions with clearly defined cardiovascular endpoints as well
as randomized trials are necessary to further examine clin-
ical consequences and possible therapeutic approaches.
However, our results indicate a need of early risk stratifica-
tion immediately after delivery. Clinical re-examinations
including risk factor modification and patient education
might represent an opportunity to prevent disease progres-
sion in females with history of gestational hyperglycemia.
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